Document Detail


Activated partial thromboplastin time and clinical outcome after thrombin inhibition in unstable coronary artery disease.
MedLine Citation:
PMID:  10543929     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
CONCLUSIONS: Higher activated partial thromboplastin time levels during inogatran treatment are related to increased risk of death, myocardial infarction or refractory angina. This might, at least in part, be explained by differences in anticoagulant mechanisms between direct thrombin inhibitors and heparin, and further emphasizes the poorly defined optimal activated partial thromboplastin time range during treatment with direct thrombin inhibitors in unstable coronary artery disease.
Authors:
J Oldgren; R Linder; L Grip; A Siegbahn; L Wallentin
Related Documents :
18411889 - Providing reliable care for patients with emergent acute myocardial infarction.
11286309 - The low-molecular-weight heparin dalteparin as adjuvant therapy in acute myocardial inf...
7265469 - Primary thrombocythemia and myocardial infarction in a 26-year-old woman with normal co...
20955429 - Protecting against ischemia-reperfusion injury: antiplatelet drugs, statins, and their ...
17174639 - Antiplatelet therapy and progression of coronary artery disease: a placebo-controlled t...
18243369 - Intermittent heparin infusion in children with ischemic heart disease caused by kawasak...
16138949 - Role of vasopressin antagonists in the management of acute decompensated heart failure.
20937949 - Watershed infarctions are more prone than other cortical infarcts to cause early-onset ...
12214169 - Pacing therapy in the elderly.
Publication Detail:
Type:  Clinical Trial; Comment; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  European heart journal     Volume:  20     ISSN:  0195-668X     ISO Abbreviation:  Eur. Heart J.     Publication Date:  1999 Nov 
Date Detail:
Created Date:  2000-01-19     Completed Date:  2000-01-19     Revised Date:  2013-05-20    
Medline Journal Info:
Nlm Unique ID:  8006263     Medline TA:  Eur Heart J     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  1657-66     Citation Subset:  IM    
Copyright Information:
Copyright 1999 The European Society of Cardiology.
Affiliation:
Department of Cardiology, Uppsala University Hospital, Uppsala.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Angina, Unstable / blood,  drug therapy*,  mortality
Antithrombins / administration & dosage*,  adverse effects
Cause of Death
Coronary Disease / blood,  drug therapy*,  mortality
Dose-Response Relationship, Drug
Female
Glycine / administration & dosage,  adverse effects,  analogs & derivatives*
Heparin / administration & dosage,  adverse effects
Humans
Infusions, Intravenous
Male
Middle Aged
Myocardial Infarction / blood,  drug therapy*,  mortality
Partial Thromboplastin Time*
Piperidines / administration & dosage*,  adverse effects
Survival Rate
Thrombin / antagonists & inhibitors*,  metabolism
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antithrombins; 0/Piperidines; 428409I84L/inogatran; 56-40-6/Glycine; 9005-49-6/Heparin; EC 3.4.21.5/Thrombin
Comments/Corrections
Comment On:
Eur Heart J. 1997 Sep;18(9):1416-25   [PMID:  9458447 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  ACE inhibition with ramipril improves left ventricular function at rest and post exercise in patient...
Next Document:  The impact of cachexia on cardiorespiratory reflex control in chronic heart failure.